Medical University of South Carolina - Cancer Center Support Grant

描述(由申请人提供)：南卡罗来纳医科大学霍林斯癌症中心(HCC)寻求通过P30癌症中心资助(CCSG)机制更新其2009年授予的国家癌症研究所(NCI)称号。作为南卡罗来纳州领先的学术医疗中心，MUSC负责建立临床、基础、转换和基于人群的研究项目，以满足该州重要的医疗需求。美国癌症委员会的使命是减轻南卡罗来纳州的癌症负担。为了完成这一使命，主任安德鲁·S·克拉夫特博士和肝细胞癌高级领导层建立了一个强大的跨学科基础，现在包括来自5所南加州大学学院和20个学术部门的122名癌症科学家。 跨学科的创新研究通过组织癌症基因和分子调控、癌症免疫学、发展癌症治疗和癌症控制四个项目来推动。快速的发现和转向有效的转化研究的步伐得到了共享研究资源的支持，其中五个资源在本申请中介绍：脂质组学、细胞评估和治疗、细胞和分子成像、生物信息库和组织分析以及生物统计学。肝细胞癌还为其临床试验办公室寻求CCSG的支持，该办公室在过去四年中介入治疗试验的应计金额大幅增加了59%。值得注意的是，2012年参加介入治疗试验的患者中有26%是少数族裔，在本项目期间增加了45%。这是由美国癌症中心领导的进步外展服务和针对南卡罗来纳州人的癌症教育所推动的。南卡罗来纳州以农村人口为主，其中包括一些美国医疗服务最匮乏的人。如今，美国国家癌症研究所每年的校外研究经费总额为4,080万美元，其中1,860万美元来自NCI，自2009年以来分别增长了31%和54%。在第一个项目期间，美国癌症中心成功地利用了CCSG的资金，以及其NCI指定的癌症中心的地位，继续保持该中心的快速增长。在本项目期间，协调中心支持了该中心的34个战略招聘工作。在南加州大学开设的两个最先进的研究设施--生物工程和药物发现大楼--带来了额外的66,156英尺的研究空间，使大学授权下的校园总面积达到270,174英尺。自2009年以来，HCC已投资530万美元引进尖端技术，并获得了另外380万美元的机构承诺，以扩大可用资源的范围。这些令人印象深刻的发展确保了肝癌科学家将继续他们的模范记录，为了解癌症生物学做出重大贡献，同时将这些发现与开发癌症控制、诊断和治疗的新方法结合起来。

DESCRIPTION (provided by applicant): The Hollings Cancer Center (HCC) at the Medical University of South Carolina (MUSC) seeks renewal of its National Cancer Institute (NCI) designation awarded in 2009 via the P30 Cancer Center Support Grant (CCSG) mechanism. As South Carolina's leading academic medical center, MUSC is charged with building clinical, basic, translational, and population-based research programs that address the state's significant healthcare needs. The mission of the HCC is to reduce the cancer burden in South Carolina. To accomplish this mission, the Director, Dr. Andrew S. Kraft, and the HCC senior leadership have established a robust, interdisciplinary base that now includes 122 cancer scientists from 5 MUSC colleges and 20 academic departments. Interdisciplinary, innovative research is driven through the organization of the HCC into four programs: Cancer Genes & Molecular Regulation, Cancer Immunology, Developmental Cancer Therapeutics, and Cancer Control. The rapid pace of discovery and movement toward effective translational research is supported by shared research resources, five of which are presented in this application: Lipidomics, Cell Evaluation & Therapy, Cell & Molecular Imaging, Biorepository & Tissue Analysis, and Biostatistics. The HCC also seeks CCSG support for its Clinical Trials Office which has spear-headed a dramatic 59% increase in accrual volume for interventional treatment trials over the last four years. Notably, 26% of patients enrolled onto interventional treatment trials in 2012 were minorities, representing a 45% increase in this project period. This has been promoted by HCC-led progressive outreach services and cancer education to South Carolinians, a largely rural population that includes some of the most medically underserved people in the US. Today, the HCC has $40.8M in annual total extramural research funding with $18.6M derived from the NCI, representing a 31% and 54% increase, respectively, since 2009. The HCC has successfully leveraged CCSG funding during the first project period and its NCI-designated Cancer Center status to continue the rapid growth of this Center. During the current project period, the HCC supported 34 strategic recruitments to the Center. The opening of two state-of-the-art research facilities at MUSC, the Bioengineering and Drug Discovery Buildings, has resulted in an additional 66,156 ft of HCC research space, bringing the total amount of space on campus under the HCC authority to 270,174 ft. The HCC has invested $5.3M since 2009 to introduce cutting-edge technologies and has secured another $3.8M in institutional commitments to increase the range of available resources. These impressive developments ensure that HCC scientists will continue their exemplary track record in making significant contributions to the understanding of cancer biology while coupling these findings to the development of novel approaches to cancer control, diagnosis, and treatment.